Cancer vaccines: Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses

Science Translational Medicine

Volumn 4, Issue 120, 2012, Pages

  Garaude, Johan ^a,b   Kent, Andrew ^a   Van Rooijen, Nico ^c   Blander, J Magarian ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b INSERM   (France)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLAGELLIN; INFLAMMASOME; MYELOID DIFFERENTIATION FACTOR 88; NEURONAL APOPTOSIS INHIBITORY PROTEIN; NEURONAL APOPTOSIS INHIBITORY PROTEIN 5; TOLL LIKE RECEPTOR 5; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BIRC1E PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; CANCER VACCINE; IPAF PROTEIN, MOUSE; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HOST RESISTANCE; IMMUNE RESPONSE; LUNG METASTASIS; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CALCIUM-BINDING PROTEINS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; FLAGELLIN; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS; NEURONAL APOPTOSIS-INHIBITORY PROTEIN; TOLL-LIKE RECEPTORS;

EID: 84856988610     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002868     Document Type: Article

References (60)

1. O. J. Finn, Cancer immunology. N. Engl. J. Med. 358, 2704-2715 (2008).
2. R. Medzhitov, Approaching the asymptote: 20 years later. Immunity 30, 766-775 (2009).
3. A. Iwasaki, R. Medzhitov, Regulation of adaptive immunity by the innate immune system. Science 327, 291-295 (2010).
4. T. Boon, J. C. Cerottini, B. Van den Eynde, P. van der Bruggen, A. Van Pel, Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12, 337-365 (1994).
5. C. G. Drake, E. Jaffee, D. M. Pardoll, Mechanisms of immune evasion by tumors. Adv. Immunol. 90, 51-81 (2006).
6. D. Gabrilovich, Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4, 941-952 (2004).
7. M. Dougan, G. Dranoff, Immune therapy for cancer. Annu. Rev. Immunol. 27, 83-117 (2009).
8. E. Gilboa, DC-based cancer vaccines. J. Clin. Invest. 117, 1195-1203 (2007).
9. K. Palucka, J. Banchereau, I. Mellman, Designing vaccines based on biology of human dendritic cell subsets. Immunity 33, 464-478 (2010).
10. H. Kanzler, F. J. Barrat, E. M. Hessel, R. L. Coffman, Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13, 552-559 (2007).
11. C. Schmidt, Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat. Biotechnol. 25, 825-826 (2007).
12. E. J. Hennessy, A. E. Parker, L. A. O'Neill, Targeting Toll-like receptors: Emerging therapeutics? Nat. Rev. Drug Discov. 9, 293-307 (2010).
13. M. Y. Gerner, K. A. Casey, M. F. Mescher, Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J. Immunol. 181, 155-164 (2008).
14. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174, 2591-2601 (2005).
15. F. Ossendorp, E. Mengedé, M. Camps, R. Filius, C. J. Melief, Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187, 693-702 (1998).
16. J. M. Blander, R. Medzhitov, Regulation of phagosome maturation by signals from Toll-like receptors. Science 304, 1014-1018 (2004).
17. J. M. Blander, R. Medzhitov, Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440, 808-812 (2006).
18. J. M. Blander, R. Medzhitov, On regulation of phagosome maturation and antigen presentation. Nat. Immunol. 7, 1029-1035 (2006).
19. S. Burgdorf, C. Schölz, A. Kautz, R. Tampé, C. Kurts, Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat. Immunol. 9, 558-566 (2008).
20. O. Schulz, S. S. Diebold, M. Chen, T. I. Näslund, M. A. Nolte, L. Alexopoulou, Y. T. Azuma, R. A. Flavell, P. Liljeström, C. Reis e Sousa, Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433, 887-892 (2005).
21. F. Hayashi, K. D. Smith, A. Ozinsky, T. R. Hawn, E. C. Yi, D. R. Goodlett, J. K. Eng, S. Akira, D. M. Underhill, A. Aderem, The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410, 1099-1103 (2001).
22. A. Didierlaurent, I. Ferrero, L. A. Otten, B. Dubois, M. Reinhardt, H. Carlsen, R. Blomhoff, S. Akira, J. P. Kraehenbuhl, J. C. Sirard, Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J. Immunol. 172, 6922-6930 (2004).
23. S. Mariathasan, K. Newton, D. M. Monack, D. Vucic, D. M. French, W. P. Lee, M. Roose-Girma, S. Erickson, V. M. Dixit, Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430, 213-218 (2004).
24. E. A. Miao, C. M. Alpuche-Aranda, M. Dors, A. E. Clark, M. W. Bader, S. I. Miller, A. Aderem, Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1b via Ipaf. Nat. Immunol. 7, 569-575 (2006).
25. K. L. Lightfield, J. Persson, S. W. Brubaker, C. E. Witte, J. von Moltke, E. A. Dunipace, T. Henry, Y. H. Sun, D. Cado, W. F. Dietrich, D. M. Monack, R. M. Tsolis, R. E. Vance, Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellin. Nat. Immunol. 9, 1171-1178 (2008).
26. Y. H. Sun, H. G. Rolán, R. M. Tsolis, Injection of flagellin into the host cell cytosol by Salmonella enterica serotype Typhimurium. J. Biol. Chem. 282, 33897-33901 (2007).
27. F. Martinon, A. Mayor, J. Tschopp, The inflammasomes: Guardians of the body. Annu. Rev. Immunol. 27, 229-265 (2009).
28. S. Jaiswal, C. H. Jamieson, W. W. Pang, C. Y. Park, M. P. Chao, R. Majeti, D. Traver, N. van Rooijen, I. L. Weissman, CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271-285 (2009).
29. K. D. Smith, E. Andersen-Nissen, F. Hayashi, K. Strobe, M. A. Bergman, S. L. Barrett, B. T. Cookson, A. Aderem, Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat. Immunol. 4, 1247-1253 (2003).
30. T. Blankenstein, Z. Qin, The role of IFN-γ in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr. Opin. Immunol. 15, 148-154 (2003).
31. P. Mombaerts, J. Iacomini, R. S. Johnson, K. Herrup, S. Tonegawa, V. E. Papaioannou, RAG-1- deficient mice have no mature B and T lymphocytes. Cell 68, 869-877 (1992).
32. + T cells. J. Exp. Med. 198, 569-580 (2003).
33. + T cells by exogenous cell-associated antigens. Immunity 17, 211-220 (2002).
34. G. Dranoff, E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, R. C. Mulligan, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90, 3539-3543 (1993).
35. D. Sancho, D. Mourão-Sá, O. P. Joffre, O. Schulz, N. C. Rogers, D. J. Pennington, J. R. Carlyle, C. Reis e Sousa, Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J. Clin. Invest. 118, 2098-2110 (2008).
36. E. Gilboa, The promise of cancer vaccines. Nat. Rev. Cancer 4, 401-411 (2004).
37. T. W. Dubensky Jr., S. G. Reed, Adjuvants for cancer vaccines. Semin. Immunol. 22, 155-161 (2010).
38. S. Tsuji, M. Matsumoto, O. Takeuchi, S. Akira, I. Azuma, A. Hayashi, K. Toyoshima, T. Seya, Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: Involvement of Toll-like receptors. Infect. Immun. 68, 6883-6890 (2000).
39. J. Uehori, K. Fukase, T. Akazawa, S. Uematsu, S. Akira, K. Funami, M. Shingai, M. Matsumoto, I. Azuma, K. Toyoshima, S. Kusumoto, T. Seya, Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: Monoacylated MDP confers TLR2/TLR4 activation. J. Immunol. 174, 7096-7103 (2005).
40. A. H. Razack, Bacillus Calmette-Guérin and bladder cancer. Asian J. Surg. 30, 302-309 (2007).
41. J. Vollmer, A. M. Krieg, Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 61, 195-204 (2009).
42. J. W. Huleatt, A. R. Jacobs, J. Tang, P.Desai, E. B. Kopp, Y.Huang, L. Song, V. Nakaar, T. J. Powell, Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25, 763-775 (2007).
43. S. Arimilli, J. B. Johnson, K. M. Clark, A. H. Graff, M. A. Alexander-Miller, S. B. Mizel, G. D. Parks, Engineered expression of the TLR5 ligand flagellin enhances paramyxovirus activation of human dendritic cell function. J. Virol. 82, 10975-10985 (2008).
44. J. W. Huleatt, V. Nakaar, P.Desai, Y. Huang, D. Hewitt, A. Jacobs, J. Tang,W.McDonald, L. Song, R. K. Evans, S. Umlauf, L. Tussey, T. J. Powell, Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26, 201-214 (2008).
45. B. Z. Wang, F. S. Quan, S. M. Kang, J. Bozja, I. Skountzou, R. W. Compans, Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J. Virol. 82, 11813-11823 (2008).
46. + cells is necessary for the adjuvant activity of flagellin. J. Immunol. 182, 7539-7547 (2009).
47. K. L. Knutson, M. L. Disis, Augmenting T helper cell immunity in cancer. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5, 365-371 (2005).
48. P. Daftarian, M. Mansour, A. C. Benoit, B. Pohajdak, D. W. Hoskin, R. G. Brown, W. M. Kast, Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 24, 5235-5244 (2006).
49. C. J. Melief, Cancer immunotherapy by dendritic cells. Immunity 29, 372-383 (2008).
50. S. R. Bennett, F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, W. R. Heath, Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478-480 (1998).
51. + T cells in anti-tumor immune responses. Immunol. Rev. 222, 129-144 (2008).
52. J. C. Sun, M. J. Bevan, Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300, 339-342 (2003).
53. I. C. Allen, E. M. TeKippe, R. M. Woodford, J. M. Uronis, E. K. Holl, A. B. Rogers, H. H. Herfarth, C. Jobin, J. P. Ting, The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 207, 1045-1056 (2010).
54. G. Y. Chen, M. Liu, F. Wang, J. Bertin, G. Núñez, A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J. Immunol. 186, 7187-7194 (2011).
55. B. Hu, E. Elinav, S. Huber, C. J. Booth, T. Strowig, C. Jin, S. C. Eisenbarth, R. A. Flavell, Inflammationinduced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc. Natl. Acad. Sci. U.S.A. 107, 21635-21640 (2010).
56. S. Normand, A. Delanoye-Crespin, A. Bressenot, L. Huot, T. Grandjean, L. Peyrin-Biroulet, Y. Lemoine, D. Hot, M. Chamaillard, Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc. Natl. Acad. Sci. U.S.A. 108, 9601-9606 (2011).
57. F. Ghiringhelli, L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma, C. Ortiz, K. Vermaelen, T. Panaretakis, G. Mignot, E. Ullrich, J. L. Perfettini, F. Schlemmer, E. Tasdemir, M. Uhl, P. Génin, A. Civas, B. Ryffel, J. Kanellopoulos, J. Tschopp, F. André, R. Lidereau, N. M. McLaughlin, N. M. Haynes, M. J. Smyth, G. Kroemer, L. Zitvogel, Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat. Med. 15, 1170-1178 (2009).
58. A. K. Abbas, K. M. Murphy, A. Sher, Functional diversity of helper T lymphocytes. Nature 383, 787-793 (1996).
59. N. Van Rooijen, A. Sanders, Liposome mediated depletion of macrophages: Mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 174, 83-93 (1994).
60. B. J. Quah, H. S. Warren, C. R. Parish, Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat. Protoc. 2, 2049-2056 (2007).